Larimar Therapeutics (LRMR) Projected to Post Earnings on Monday

Larimar Therapeutics (NASDAQ:LRMR) will likely be posting its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 12:30 PM ET.

Larimar Therapeutics (NASDAQ:LRMR) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.30). On average, analysts expect Larimar Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Larimar Therapeutics Stock Performance

Shares of LRMR opened at $4.62 on Friday. The firm’s 50 day moving average price is $4.09 and its 200 day moving average price is $3.95. Larimar Therapeutics has a twelve month low of $1.61 and a twelve month high of $6.42. The firm has a market cap of $479.93 million, a PE ratio of -2.09 and a beta of 0.91.

Insider Transactions at Larimar Therapeutics

In other Larimar Therapeutics news, Director James E. Flynn bought 5,000,000 shares of the stock in a transaction on Friday, February 27th. The stock was purchased at an average price of $5.00 per share, with a total value of $25,000,000.00. Following the acquisition, the director owned 10,622,957 shares of the company’s stock, valued at approximately $53,114,785. The trade was a 88.92% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of LRMR. Deerfield Management Company L.P. raised its stake in Larimar Therapeutics by 44.2% in the 3rd quarter. Deerfield Management Company L.P. now owns 30,606,974 shares of the company’s stock valued at $98,861,000 after acquiring an additional 9,375,000 shares during the period. Opaleye Management Inc. lifted its holdings in shares of Larimar Therapeutics by 114.7% during the 2nd quarter. Opaleye Management Inc. now owns 4,110,000 shares of the company’s stock worth $11,878,000 after acquiring an additional 2,195,923 shares during the period. Woodline Partners LP lifted its holdings in shares of Larimar Therapeutics by 160.6% in the third quarter. Woodline Partners LP now owns 1,622,850 shares of the company’s stock worth $5,242,000 after acquiring an additional 1,000,168 shares during the last quarter. Vanguard Group Inc. lifted its stake in Larimar Therapeutics by 44.2% in the 3rd quarter. Vanguard Group Inc. now owns 3,087,840 shares of the company’s stock valued at $9,974,000 after purchasing an additional 945,809 shares during the last quarter. Finally, Federated Hermes Inc. increased its stake in shares of Larimar Therapeutics by 14,885.7% in the fourth quarter. Federated Hermes Inc. now owns 358,907 shares of the company’s stock valued at $1,367,000 after buying an additional 356,512 shares during the period. 91.92% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Citigroup lifted their price objective on shares of Larimar Therapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Lifesci Capital raised Larimar Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 24th. Wedbush upped their price target on Larimar Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Friday, March 20th. Leerink Partners raised Larimar Therapeutics to a “strong-buy” rating in a report on Monday, January 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Larimar Therapeutics in a research note on Thursday, January 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Larimar Therapeutics presently has an average rating of “Buy” and an average target price of $16.50.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.